Rejuve.Bio Launches Groundbreaking Crowd Fund on NetCapital to Pioneer the Future of Artificial General Intelligence and Longevity
LOS ANGELES, March 12, 2024 /PRNewswire/ -- Rejuve.Bio, a leading AI biotechnology firm at the forefront of the longevity revolution, announces its latest initiative: a Crowd Fundraise on the NetCapital platform. This pivotal move opens a gateway for investors to be part of a transformative journey, leveraging artificial intelligence and genetics to challenge the conventional notions of aging and human healthspan. [See https://netcapital.com/companies/rejuvebiotech for more information.]
- LOS ANGELES, March 12, 2024 /PRNewswire/ -- Rejuve.Bio, a leading AI biotechnology firm at the forefront of the longevity revolution, announces its latest initiative: a Crowd Fundraise on the NetCapital platform.
- This pivotal move opens a gateway for investors to be part of a transformative journey, leveraging artificial intelligence and genetics to challenge the conventional notions of aging and human healthspan.
- Focused on harnessing the power of artificial intelligence (AI) and genetics, Rejuve.Bio aims to revolutionize the healthcare and biotech industries by extending human healthspan and redefining the aging process.
- All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns.